Table 4.
IFNγ ELISpot T-cell responses at baseline, circulating virus sequence vs. vaccine insert. A) HLA-B8 epitope, B) HLA-A2 epitope, C) Epitope of unknown HLA restriction.
| (A) | Patient | H | S | K | K | K | C | D | E | L | (B) | Patient | K | L | S | G | L | G | I | N | A | V | (C) | Patient | S | R | A | R | P | R | W | F | M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HLA-B8 + ve pts |
359 | - | - | - | R | - | - | - | - | - | HLA-A2 +ve pts |
357 | - | - | V | A | - | - | V | - | - | - | 357 | - | - | - | - | - | - | - | - | W | |
| 359pv | - | - | - | R | - | - | - | - | - | 351 | - | - | - | A | - | - | L | - | - | - | 351 | - | - | - | - | - | - | - | - | - | |||
| 354 | - | - | - | - | - | - | - | - | - | 354 | - | - | T | A | M | - | - | - | - | - | 354 | - | H | - | - | - | - | - | - | W | |||
| 362 | - | - | - | - | - | - | - | - | - | 355 | - | - | V | A | - | - | V | - | - | - | 355 | - | - | - | - | - | - | - | - | W | |||
| HLA-B8 neg pts |
357 | - | - | - | - | - | - | - | - | - | 355pv | - | - | V | A | - | - | V | - | - | - | 355pv | - | - | - | - | - | - | - | - | W | ||
| 350 | - | - | - | - | - | - | - | - | - | 360 | - | - | V | A | - | - | - | - | - | - | 360 | - | - | - | - | - | - | - | - | W | |||
| 351 | - | - | - | - | - | - | - | - | - | 360pv | - | - | V | A | - | - | - | - | - | - | 360pv | - | - | - | - | - | - | - | - | W | |||
| 352 | - | - | - | - | - | - | - | - | - | 366 | - | - | V | S | - | - | - | - | - | - | 366 | - | H | - | - | - | - | - | - | W | |||
| 356 | - | - | - | - | - | - | - | - | - | HLA-A2 Neg pts |
350 | - | - | V | A | - | - | - | - | - | - | 350 | - | - | - | - | - | - | - | - | W | ||
| 355 | - | - | - | - | - | - | - | - | - | 352 | - | - | V | A | - | - | V | - | - | - | 352 | - | - | - | - | - | - | - | - | W | |||
| 355pv | - | - | - | - | - | - | - | - | - | 356 | - | - | - | - | - | - | L | - | - | - | 356 | - | - | - | - | - | - | - | I | - | |||
| 358 | - | - | - | - | - | - | - | - | - | 358 | - | - | V | A | - | - | V | - | - | - | 358 | - | - | - | - | - | - | - | - | W | |||
| 358 pv | - | - | - | - | - | - | - | - | - | 358pv | - | - | V | A | - | - | V | - | - | - | 358pv | - | - | - | - | - | - | - | - | W | |||
| 360 | - | - | - | - | - | - | - | - | - | 359 | - | - | V | A | - | - | V | - | - | - | 359 | - | - | - | - | - | - | - | - | W | |||
| 360pv | - | - | - | - | - | - | - | - | - | 359 | - | - | V | A | - | - | V | - | - | - | 359pv | - | - | - | - | - | - | - | - | W | |||
| 364 | n.d | 364 | n.d | 364 | n.d | ||||||||||||||||||||||||||||
| 366 | - | - | - | - | - | - | - | - | - | 362 | - | - | V | A | - | - | - | - | - | - | 362 | - | - | - | - | - | - | - | L | W | |||
Viral sequence was determined at baseline and 2 weeks post-vaccination (pv; untreated patients only). The HCV vaccine immunogen sequence is given in the top line of each table. A dashed line below indicates that an amino acid is identical to that in the vaccine immunogen. The epitopes to which individual patients have made a T-cell response (as measured by ex vivo IFNγ-ELISpot assay) are shown in bold red font.